1 Report Prologue
2 Market Introduction
2.1 Definition 19
2.2 Scope of Study 19
2.3 Research Objective 19
2.4 Assumptions & Limitations 20
2.4.1 Assumptions 20
2.4.2 Limitations 20
2.5 Market Structure 20
3 Research Methodology
3.1.1 Primary Research Methodology 22
3.1.2 Secondary Research Methodology 23
3.1.3 Market Share Analysis 23
3.1.4 Market Pricing Approach 23
4 Market Dynamics
4.1 Introduction 25
4.2 Drivers 26
4.2.1 Increasing Prevalence of Diabetes and Atherosclerosis (Impact Weightage 40%) 26
4.2.2 Change in Lifestyle (Impact Weightage 35%) 27
4.2.3 Increasing Prevalence of Glaucoma, Lymphoma, and Multiple Myeloma (Impact Weightage 25%) 28
4.3 Restraints 29
4.3.1 Side Effect of Treatment (Impact Weightage 60%) 29
4.3.2 High Cost of Treatment (Impact Weightage 40%) 30
5 Market Factor Analysis
5.1 Porters Five Forces Model 31
5.1.1 Bargaining Power of Suppliers 32
5.1.2 Bargaining Power of Buyers 32
5.1.3 Threat of New Entrants 32
5.1.4 Threat of Substitutes 32
5.1.5 Intensity of Rivalry 33
5.2 Value Chain Analysis 33
5.2.1 R&D 33
5.2.2 Manufacturing 34
5.2.3 Distribution & Sales 34
5.2.4 Post–sales Monitoring 34
5.3 Demand & Supply: Gap Analysis 35
5.4 Pricing Analysis 35
5.5 Investment Opportunity Analysis 35
6 Global Retinal Vein Occlusion Market, By Type
6.1 Branch Retinal Artery Occlusion 37
6.2 Central Retinal Vein Occlusion 37
7 Global Retinal Vein Occlusion Market, By Condition
7.1 Non–Ischemic 39
7.2 Ischemic 39
8 Global Retinal Vein Occlusion Market, By Diagnosis
8.1 Optical Coherence Tomography 41
8.2 Fundoscopic Examination 41
8.3 Fluorescein Angiography 42
9 Global Retinal Vein Occlusion Market, By Treatment
9.1 Antivascular Endothelial Growth Factor 44
9.1.1 Aflibercept 44
9.1.2 Ranibizumab 45
9.2 Corticosteroid Drugs 45
9.2.1 Triamcinolone Acetonide 46
9.2.2 Dexamethasone 46
9.3 Laser Retinal Photocoagulation 47
10 Global Retinal Vein Occlusion Market, By End User
10.1 Hospitals and Clinics 49
10.2 Research & Academics Centers 49
11 Global Retinal Vein Occlusion Market, By Region
11.1 Americas 50
11.1.1 North America 54
11.1.1.1 U.S 57
11.1.1.2 Canada 60
11.1.2 South America 63
11.2 Europe 66
11.2.1 Western Europe 70
11.2.1.1 Germany 74
11.2.1.2 France 77
11.2.1.3 UK 80
11.2.1.4 Italy 83
11.2.1.5 Spain 86
11.2.1.6 Rest of Western Europe 89
11.2.2 Eastern Europe 92
11.3 Asia–Pacific 96
11.3.1 Japan 101
11.3.2 China 104
11.3.3 India 107
11.3.4 Australia 110
11.3.5 Republic of Korea 113
11.3.6 Rest of Asia–Pacific 116
11.4 Middle East & Africa 120
11.4.1 Africa 128
12 Competitive Landscape
12.1 Introduction 131
12.2 Company Share Analysis 131
13 Company Profiles
13.1 Allergan PLC 132
13.1.1 Company Overview 132
13.1.2 Financials 132
13.1.3 Products 132
13.1.4 Strategy 132
13.1.5 Key Developments 132
13.2 Bayer 133
13.2.1 Company Overview 133
13.2.2 Financials 133
13.2.3 Products 133
13.2.4 Strategy 133
13.2.5 Key Developments 133
13.3 Bristol–Myers Squibb 134
13.3.1 Company Overview 134
13.3.2 Financials 134
13.3.3 Products 134
13.3.4 Strategy 134
13.3.5 Key Developments 134
13.4 Ellex Medical Lasers Ltd. 135
13.4.1 Company Overview 135
13.4.2 Financials 135
13.4.3 Products 135
13.4.4 Strategy 135
13.4.5 Key Developments 135
13.5 GlaxoSmithKline PLC 136
13.5.1 Company Overview 136
13.5.2 Financials 136
13.5.3 Products 136
13.5.4 Strategy 136
13.5.5 Key Developments 136
13.6 IRIDEX Corporation 137
13.6.1 Company Overview 137
13.6.2 Financials 137
13.6.3 Products 137
13.6.4 Strategy 137
13.6.5 Key Developments 137
13.7 Lumenis 138
13.7.1 Company Overview 138
13.7.2 Financials 138
13.7.3 Products 138
13.7.4 Strategy 138
13.7.5 Key Developments 138
13.8 Novartis 139
13.8.1 Company Overview 139
13.8.2 Financials 139
13.8.3 Products 139
13.8.4 Strategy 139
13.8.5 Key Developments 139
13.9 NIDEK CO., LTD. 140
13.9.1 Company Overview 140
13.9.2 Financials 140
13.9.3 Products 140
13.9.4 Strategy 140
13.9.5 Key Developments 140
13.10 Regeneron Pharmaceuticals 141
13.10.1 Company Overview 141
13.10.2 Financials 141
13.10.3 Products 141
13.10.4 Strategy 141
13.10.5 Key Developments 141
13.11 F. Hoffmann–La Roche AG 142
13.11.1 Company Overview 142
13.11.2 Financials 142
13.11.3 Products 142
13.11.4 Strategy 142
13.11.5 Key Developments 142
13.12 Quantel Medical Inc. 143
13.12.1 Company Overview 143
13.12.2 Financials 143
13.12.3 Products 143
13.12.4 Strategy 143
13.12.5 Key Developments 143
13.13 Topcon Medical Systems, Inc. 144
13.13.1 Company Overview 144
13.13.2 Financials 144
13.13.3 Products 144
13.13.4 Strategy 144
13.13.5 Key Developments 144
13.14 ZEISS 145
13.14.1 Company Overview 145
13.14.2 Financials 145
13.14.3 Products 145
13.14.4 Strategy 145
13.14.5 Key Developments 145
14 MRFR Conclusion
14.1 Key Findings 146
14.1.1 From CEO’s View Point 146
14.1.2 Unmet Needs 146
14.2 Key companies to watch 146
15 Appendix
15.1 Discussion Blue Print 147
16 List of Tables
TABLE 1 PRIMARY INTERVIEWS 22
TABLE 2 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR BRANCH RETINAL ARTERY OCCLUSION, BY REGION, 2020–2027 (USD MILLION) 37
TABLE 3 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2020–2027 (USD MILLION) 37
TABLE 4 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR NON–ISCHEMIC, BY REGION, 2020–2027 (USD MILLION) 39
TABLE 5 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR ISCHEMIC, BY REGION, 2020–2027 (USD MILLION) 39
TABLE 6 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 41
TABLE 7 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR FUNDOSCOPIC EXAMINATION, BY REGION, 2020–2027 (USD MILLION) 41
TABLE 8 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR FLUORESCEIN ANGIOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 42
TABLE 9 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2020–2027 (USD MILLION) 44
TABLE 10 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR AFLIBERCEPT, BY REGION, 2020–2027 (USD MILLION) 44
TABLE 11 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR RANIBIZUMAB, BY REGION, 2020–2027 (USD MILLION) 45
TABLE 12 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR CORTICOSTEROID DRUGS, BY REGION, 2020–2027 (USD MILLION) 45
TABLE 13 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR TRIAMCINOLONE ACETONIDE, BY REGION, 2020–2027 (USD MILLION) 46
TABLE 14 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR DEXAMETHASONE, BY REGION, 2020–2027 (USD MILLION) 46
TABLE 15 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR LASER RETINAL PHOTOCOAGULATION, BY REGION, 2020–2027 (USD MILLION) 47
TABLE 16 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2020–2027 (USD MILLION) 49
TABLE 17 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR RESEARCH & ACADEMICS CENTERS, BY REGION, 2020–2027 (USD MILLION) 49
TABLE 18 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY REGION, 2020–2027 (USD MILLION) 51
TABLE 19 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 51
TABLE 20 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 51
TABLE 21 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 52
TABLE 22 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 52
TABLE 23 AMERICAS ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 53
TABLE 24 AMERICAS CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53
TABLE 25 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 53
TABLE 26 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 54
TABLE 27 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 54
TABLE 28 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 54
TABLE 29 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 55
TABLE 30 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55
TABLE 31 NORTH AMERICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 56
TABLE 32 NORTH AMERICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 56
TABLE 33 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 56
TABLE 34 US RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 57
TABLE 35 US RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 57
TABLE 36 US RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 57
TABLE 37 US RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 58
TABLE 38 US ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 58
TABLE 39 US CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59
TABLE 40 US RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 59
TABLE 41 CANADA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 60
TABLE 42 CANADA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 60
TABLE 43 CANADA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 60
TABLE 44 CANADA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 61
TABLE 45 CANADA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 61
TABLE 46 CANADA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62
TABLE 47 CANADA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 62
TABLE 48 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 63
TABLE 49 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 63
TABLE 50 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 64
TABLE 51 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 64
TABLE 52 SOUTH AMERICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 65
TABLE 53 SOUTH AMERICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65
TABLE 54 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 65
TABLE 55 EUROPE RETINAL VEIN OCCLUSION MARKET, BY REGION, 2020–2027 (USD MILLION) 67
TABLE 56 EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 67
TABLE 57 EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 67
TABLE 58 EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 68
TABLE 59 EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 68
TABLE 60 EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 69
TABLE 61 EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 69
TABLE 62 EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 69
TABLE 63 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 64 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 70
TABLE 65 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 71
TABLE 66 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 71
TABLE 67 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 72
TABLE 68 WESTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 72
TABLE 69 WESTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 73
TABLE 70 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 73
TABLE 71 GERMANY RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 74
TABLE 72 GERMANY RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 74
TABLE 73 GERMANY RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 74
TABLE 74 GERMANY RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 75
TABLE 75 GERMANY ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 75
TABLE 76 GERMANY CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 76
TABLE 77 GERMANY RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 76
TABLE 78 FRANCE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 79 FRANCE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 77
TABLE 80 FRANCE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 77
TABLE 81 FRANCE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 78
TABLE 82 FRANCE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 83 FRANCE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79
TABLE 84 FRANCE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 79
TABLE 85 UK RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 80
TABLE 86 UK RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 80
TABLE 87 UK RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 80
TABLE 88 UK RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 81
TABLE 89 UK ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 90 UK CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 82
TABLE 91 UK RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 82
TABLE 92 ITALY RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 83
TABLE 93 ITALY RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 83
TABLE 94 ITALY RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 83
TABLE 95 ITALY RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 84
TABLE 96 ITALY ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 97 ITALY CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85
TABLE 98 ITALY RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 85
TABLE 99 SPAIN RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 100 SPAIN RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 86
TABLE 101 SPAIN RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 86
TABLE 102 SPAIN RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 87
TABLE 103 SPAIN ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 104 SPAIN CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 105 SPAIN RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 88
TABLE 106 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 107 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 89
TABLE 108 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90
TABLE 109 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 90
TABLE 110 REST OF WESTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 91
TABLE 111 REST OF WESTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 91
TABLE 112 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 92
TABLE 113 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 114 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 93
TABLE 115 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 93
TABLE 116 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 94
TABLE 117 EASTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 94
TABLE 118 EASTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 95
TABLE 119 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 95
TABLE 120 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 121 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 97
TABLE 122 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 98
TABLE 123 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 98
TABLE 124 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 99
TABLE 125 ASIA-PACIFIC ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 99
TABLE 126 ASIA-PACIFIC CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 127 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 100
TABLE 128 JAPAN RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 101
TABLE 129 JAPAN RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 101
TABLE 130 JAPAN RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 101
TABLE 131 JAPAN RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 102
TABLE 132 JAPAN ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 102
TABLE 133 JAPAN CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 134 JAPAN RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 103
TABLE 135 CHINA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 136 CHINA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 104
TABLE 137 CHINA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 104
TABLE 138 CHINA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 105
TABLE 139 CHINA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 140 CHINA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 106
TABLE 141 CHINA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 106
TABLE 142 INDIA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 107
TABLE 143 INDIA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 107
TABLE 144 INDIA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 107
TABLE 145 INDIA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 108
TABLE 146 INDIA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 147 INDIA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 148 INDIA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 109
TABLE 149 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 150 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 110
TABLE 151 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 110
TABLE 152 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 111
TABLE 153 AUSTRALIA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 154 AUSTRALIA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 155 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 112
TABLE 156 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 157 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 113
TABLE 158 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 114
TABLE 159 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 114
TABLE 160 REPUBLIC OF KOREA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 161 REPUBLIC OF KOREA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 162 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 116
TABLE 163 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 164 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 116
TABLE 165 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 117
TABLE 166 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 117
TABLE 167 REST OF ASIA-PACIFIC ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 168 REST OF ASIA-PACIFIC CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 169 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 119
TABLE 170 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY REGION, 2020–2027 (USD MILLION) 121
TABLE 171 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 172 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 122
TABLE 173 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, AW2020–2027 (USD MILLION) 122
TABLE 174 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 123
TABLE 175 THE MIDDLE EAST & AFRICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 176 THE MIDDLE EAST & AFRICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 177 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 124
TABLE 178 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 179 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 125
TABLE 180 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 125
TABLE 181 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 126
TABLE 182 THE MIDDLE EAST ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 126
TABLE 183 THE MIDDLE EAST CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 184 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 127
TABLE 185 AFRICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 186 AFRICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 128
TABLE 187 AFRICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 128
TABLE 188 AFRICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 129
TABLE 189 AFRICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 190 AFRICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 191 RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 130
17 List of Figures
FIGURE 1 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020 (%) 16
FIGURE 2 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020 (%) 16
FIGURE 3 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020 (%) 17
FIGURE 4 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020 (%) 17
FIGURE 5 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020 (%) 18
FIGURE 6 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY REGION, 2020 (%) 18
FIGURE 7 MARKET STRUCTURE OF GLOBAL RETINAL VEIN OCCLUSION MARKET 20
FIGURE 8 RESEARCH METHODOLOGY 21
FIGURE 9 GLOBAL RETINAL VEIN OCCLUSION MARKET: FORECAST MODEL 24
FIGURE 10 PORTER’S FIVE FORCES MODEL 31
FIGURE 11 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 36
FIGURE 12 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020 & 2027 (USD MILLION) 38
FIGURE 13 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020 & 2027 (USD MILLION) 40
FIGURE 14 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020 & 2027 (USD MILLION) 43
FIGURE 15 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020 & 2027 (USD MILLION) 48
